PURPOSE: Galectin-3 expression is modulated in cancer cells, and that finding has led to the recognition of galectin-3 as a diagnostic or prognostic marker for various cancers, including breast cancer. This study investigated the correlation between galectin-3 expression and the clinicopathological features in patients with breast cancer, in order to determine the relevance and role of galectin-3 in breast cancer progression. METHODS: Galectin-3 expression was investigated immunohistochemically in 116 patients with breast cancer, and a statistical analysis was performed. RESULTS: Galectin-3 expression in breast cancer was significantly associated with tumor vascular invasion. However, galectin-3 expression was not associated with Ki-67 expression, which reflects tumor proliferation. Disease-free survival and long-term overall survival were significantly shorter for patients with reduced galectin-3 expression. CONCLUSIONS: This study demonstrated that the galectin-3 expression was associated with tumor vascular invasion and metastasis, suggesting that galectin-3 plays a critical role in tumor progression via an invasive mechanism but not via proliferation in breast cancer. Furthermore, reduced expression of galectin-3 is useful for predicting a long-term poor prognosis in patients with breast cancer.
PURPOSE:Galectin-3 expression is modulated in cancer cells, and that finding has led to the recognition of galectin-3 as a diagnostic or prognostic marker for various cancers, including breast cancer. This study investigated the correlation between galectin-3 expression and the clinicopathological features in patients with breast cancer, in order to determine the relevance and role of galectin-3 in breast cancer progression. METHODS:Galectin-3 expression was investigated immunohistochemically in 116 patients with breast cancer, and a statistical analysis was performed. RESULTS:Galectin-3 expression in breast cancer was significantly associated with tumor vascular invasion. However, galectin-3 expression was not associated with Ki-67 expression, which reflects tumor proliferation. Disease-free survival and long-term overall survival were significantly shorter for patients with reduced galectin-3 expression. CONCLUSIONS: This study demonstrated that the galectin-3 expression was associated with tumor vascular invasion and metastasis, suggesting that galectin-3 plays a critical role in tumor progression via an invasive mechanism but not via proliferation in breast cancer. Furthermore, reduced expression of galectin-3 is useful for predicting a long-term poor prognosis in patients with breast cancer.
Authors: Y Honjo; H Inohara; S Akahani; T Yoshii; Y Takenaka; J Yoshida; K Hattori; Y Tomiyama; A Raz; T Kubo Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: Leena Hilakivi-Clarke; Anni Wärri; Kerrie B Bouker; Xiyuan Zhang; Katherine L Cook; Lu Jin; Alan Zwart; Nguyen Nguyen; Rong Hu; M Idalia Cruz; Sonia de Assis; Xiao Wang; Jason Xuan; Yue Wang; Bryan Wehrenberg; Robert Clarke Journal: J Natl Cancer Inst Date: 2016-09-08 Impact factor: 13.506
Authors: Anneliese Fortuna-Costa; Angélica M Gomes; Eliene O Kozlowski; Mariana P Stelling; Mauro S G Pavão Journal: Front Oncol Date: 2014-06-16 Impact factor: 6.244
Authors: Hong Jun Kim; Min Jee Jo; Bo Ram Kim; Jung Lim Kim; Yoon A Jeong; Yoo Jin Na; Seong Hye Park; Suk-Young Lee; Dae-Hee Lee; Hye Seung Lee; Baek-Hui Kim; Sun Il Lee; Byung Wook Min; Young Do Yoo; Sang Cheul Oh Journal: PLoS One Date: 2017-05-04 Impact factor: 3.240